Anjeso is a drug owned by Baudax Bio Inc. It is protected by 8 US drug patents filed from 2020 to 2022. Out of these, 5 drug patents are active and 3 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 08, 2039. Details of Anjeso's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10881663 | Method of treating pain in elderly patients with mild renal impairment |
Mar, 2039
(14 years from now) | Active |
| US11458145 | Methods of administering intravenous meloxicam in a bolus dose |
Mar, 2039
(14 years from now) | Active |
| US11253478 | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
May, 2030
(5 years from now) | Active |
| US10709713 | Nanoparticulate meloxicam formulations |
May, 2030
(5 years from now) | Active |
| US9974746 | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
May, 2030
(5 years from now) | Active |
| US10463673 | Nanoparticulate meloxicam formulations |
Feb, 2024
(8 months ago) |
Expired
|
| US10471067 | Nanoparticulate meloxicam formulations |
Feb, 2024
(8 months ago) |
Expired
|
| US8512727 | Nanoparticulate meloxicam formulations |
Dec, 2022
(1 year, 10 months ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Anjeso's patents.
Latest Legal Activities on Anjeso's Patents
Given below is the list of recent legal activities going on the following patents of Anjeso.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Jul, 2024 | US10881663 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Jan, 2024 | US10709713 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 06 Nov, 2023 | US10709713 |
| Surcharge for Late Payment, Large Entity | 22 Aug, 2023 | US10463673 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Aug, 2023 | US10463673 (Litigated) |
| Electronic Review Critical | 28 Jun, 2023 | US10471067 (Litigated) |
| Email Notification Critical | 28 Jun, 2023 | US10471067 (Litigated) |
| Change in Power of Attorney (May Include Associate POA) Critical | 28 Jun, 2023 | US10471067 (Litigated) |
| Electronic Review Critical | 28 Jun, 2023 | US10463673 (Litigated) |
| Change in Power of Attorney (May Include Associate POA) Critical | 28 Jun, 2023 | US10463673 (Litigated) |
FDA has granted several exclusivities to Anjeso. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Anjeso, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Anjeso.
Exclusivity Information
Anjeso holds 1 exclusivities. All of its exclusivities have expired in 2023. Details of Anjeso's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 20, 2023 |
US patents provide insights into the exclusivity only within the United States, but Anjeso is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Anjeso's family patents as well as insights into ongoing legal events on those patents.
Anjeso's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Anjeso's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 08, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Anjeso Generic API suppliers:
Meloxicam is the generic name for the brand Anjeso. 25 different companies have already filed for the generic of Anjeso, with Aiping Pharm Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Anjeso's generic
Alternative Brands for Anjeso
Anjeso which is used for managing moderate-to-severe pain in various administration methods and conditions., has several other brand drugs using the same active ingredient (Meloxicam). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Avondale Pharms |
| |
| Heron Theraps Inc |
| |
| Iceutica Operations |
| |
| Tersera |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Meloxicam, Anjeso's active ingredient. Check the complete list of approved generic manufacturers for Anjeso
About Anjeso
Anjeso is a drug owned by Baudax Bio Inc. It is used for managing moderate-to-severe pain in various administration methods and conditions. Anjeso uses Meloxicam as an active ingredient. Anjeso was launched by Baudax in 2020.
Approval Date:
Anjeso was approved by FDA for market use on 20 February, 2020.
Active Ingredient:
Anjeso uses Meloxicam as the active ingredient. Check out other Drugs and Companies using Meloxicam ingredient
Treatment:
Anjeso is used for managing moderate-to-severe pain in various administration methods and conditions.
Dosage:
Anjeso is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 30MG/ML (30MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION | Discontinued | INTRAVENOUS |